Dr Ted Fjällman is a Partner at Flerie Invest and has been the CEO of Prokarium since 2014. He is also a member of the Board at Amarna Therapeutics. His previous assignments include positions in clinical research at Sahlgrenska University Hospital and in strategy consulting at Sweden’s Royal Academy of Engineering Sciences, where he coordinated the country’s national innovation strategy. He is also committed to promoting science and innovation in society and in 2009 Ted became one of the 45 finalists out of 8300 European Astronaut Selection candidates. Ted is an active member in the UK BioIndustry Association (BIA) and holds a PhD in Biotechnology and Immunology from the University of Guelph, Canada.
Sign up for the Beactica newsletter to receive our latest news and updates